Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study

Purpose: Concerns of drug–drug interactions (DDIs) between anti-seizure medications (ASMs) and non-vitamin K oral anticoagulants (NOACs) have emerged in recent case reports and guidelines. Theoretically, the induction of hepatic cytochrome P450 3A4 (CYP3A4) enzyme and permeability glycoprotein (P-GP...

Full description

Bibliographic Details
Main Authors: Chen-Jui Ho, Shih-Hsuan Chen, Chih-Hsiang Lin, Yan-Ting Lu, Che-Wei Hsu, Meng-Han Tsai
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Neurology
Subjects:
ASM
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2020.588053/full
id doaj-25bd43c00b9a43cb8966f038f1758122
record_format Article
spelling doaj-25bd43c00b9a43cb8966f038f17581222021-02-26T06:50:32ZengFrontiers Media S.A.Frontiers in Neurology1664-22952021-02-011110.3389/fneur.2020.588053588053Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort StudyChen-Jui Ho0Shih-Hsuan Chen1Chih-Hsiang Lin2Yan-Ting Lu3Che-Wei Hsu4Meng-Han Tsai5Meng-Han Tsai6Department of Neurology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, TaiwanDepartment of Neurology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, TaiwanDepartment of Neurology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, TaiwanDepartment of Neurology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, TaiwanDepartment of Neurology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, TaiwanDepartment of Neurology, College of Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Kaohsiung, TaiwanSchool of Medicine, College of Medicine, Chang Gung University, Taoyuan, TaiwanPurpose: Concerns of drug–drug interactions (DDIs) between anti-seizure medications (ASMs) and non-vitamin K oral anticoagulants (NOACs) have emerged in recent case reports and guidelines. Theoretically, the induction of hepatic cytochrome P450 3A4 (CYP3A4) enzyme and permeability glycoprotein (P-GP) efflux transporter protein systems may reduce the effect of NOACs. We aimed to investigate whether such DDIs are clinically relevant in a real-world situation.Methods: We retrospectively reviewed 320 ischemic stroke patients with atrial fibrillation (Af) and grouped them according to different potential interactions with CYP3A4 and P-GP. Ischemic stroke events, transient ischemic attack (TIA) events, follow-up duration, baseline characteristics, concomitant ASMs, and stroke risk factors were collected. Statistical analysis included Kaplan–Meier survival curves and the log-rank test.Results: Overall, 320 ischemic stroke with Af patients received NOACs. Among the NOAC users, 75 also took ASMs, including 56 that have potential DDIs: 43 (13.4%) were categorized as potential CYP and P-GP DDIs and 13 (4.1%) as P-GP-only DDIs. The remaining 264 (82.5%) patients were used as controls including 19 exposed to nonsignificant DDI ASMs and 245 patients without ASM exposure. The incidence rates of recurrent stroke/TIA events in both CYP3A4 and P-GP DDIs, P-GP DDIs only, and no DDIs were 7.5, 2.1, and 8.4/100 person-years, respectively. Kaplan–Meier survival curves and the log-rank test did not show significant differences among the groups.Conclusions: The recurrent stroke rate of NOAC users with potential DDIs was not higher than in those without potential DDIs in this single-institute study. Our results suggest that theoretical interactions between ASMs and NOACs may not be as severe as previously thought in a real-world situation.https://www.frontiersin.org/articles/10.3389/fneur.2020.588053/fullepilepsyASMdrug–drug interactionstrokeNOAC
collection DOAJ
language English
format Article
sources DOAJ
author Chen-Jui Ho
Shih-Hsuan Chen
Chih-Hsiang Lin
Yan-Ting Lu
Che-Wei Hsu
Meng-Han Tsai
Meng-Han Tsai
spellingShingle Chen-Jui Ho
Shih-Hsuan Chen
Chih-Hsiang Lin
Yan-Ting Lu
Che-Wei Hsu
Meng-Han Tsai
Meng-Han Tsai
Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study
Frontiers in Neurology
epilepsy
ASM
drug–drug interaction
stroke
NOAC
author_facet Chen-Jui Ho
Shih-Hsuan Chen
Chih-Hsiang Lin
Yan-Ting Lu
Che-Wei Hsu
Meng-Han Tsai
Meng-Han Tsai
author_sort Chen-Jui Ho
title Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study
title_short Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study
title_full Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study
title_fullStr Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study
title_full_unstemmed Non-vitamin K Oral Anticoagulants and Anti-seizure Medications: A Retrospective Cohort Study
title_sort non-vitamin k oral anticoagulants and anti-seizure medications: a retrospective cohort study
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2021-02-01
description Purpose: Concerns of drug–drug interactions (DDIs) between anti-seizure medications (ASMs) and non-vitamin K oral anticoagulants (NOACs) have emerged in recent case reports and guidelines. Theoretically, the induction of hepatic cytochrome P450 3A4 (CYP3A4) enzyme and permeability glycoprotein (P-GP) efflux transporter protein systems may reduce the effect of NOACs. We aimed to investigate whether such DDIs are clinically relevant in a real-world situation.Methods: We retrospectively reviewed 320 ischemic stroke patients with atrial fibrillation (Af) and grouped them according to different potential interactions with CYP3A4 and P-GP. Ischemic stroke events, transient ischemic attack (TIA) events, follow-up duration, baseline characteristics, concomitant ASMs, and stroke risk factors were collected. Statistical analysis included Kaplan–Meier survival curves and the log-rank test.Results: Overall, 320 ischemic stroke with Af patients received NOACs. Among the NOAC users, 75 also took ASMs, including 56 that have potential DDIs: 43 (13.4%) were categorized as potential CYP and P-GP DDIs and 13 (4.1%) as P-GP-only DDIs. The remaining 264 (82.5%) patients were used as controls including 19 exposed to nonsignificant DDI ASMs and 245 patients without ASM exposure. The incidence rates of recurrent stroke/TIA events in both CYP3A4 and P-GP DDIs, P-GP DDIs only, and no DDIs were 7.5, 2.1, and 8.4/100 person-years, respectively. Kaplan–Meier survival curves and the log-rank test did not show significant differences among the groups.Conclusions: The recurrent stroke rate of NOAC users with potential DDIs was not higher than in those without potential DDIs in this single-institute study. Our results suggest that theoretical interactions between ASMs and NOACs may not be as severe as previously thought in a real-world situation.
topic epilepsy
ASM
drug–drug interaction
stroke
NOAC
url https://www.frontiersin.org/articles/10.3389/fneur.2020.588053/full
work_keys_str_mv AT chenjuiho nonvitaminkoralanticoagulantsandantiseizuremedicationsaretrospectivecohortstudy
AT shihhsuanchen nonvitaminkoralanticoagulantsandantiseizuremedicationsaretrospectivecohortstudy
AT chihhsianglin nonvitaminkoralanticoagulantsandantiseizuremedicationsaretrospectivecohortstudy
AT yantinglu nonvitaminkoralanticoagulantsandantiseizuremedicationsaretrospectivecohortstudy
AT cheweihsu nonvitaminkoralanticoagulantsandantiseizuremedicationsaretrospectivecohortstudy
AT menghantsai nonvitaminkoralanticoagulantsandantiseizuremedicationsaretrospectivecohortstudy
AT menghantsai nonvitaminkoralanticoagulantsandantiseizuremedicationsaretrospectivecohortstudy
_version_ 1724249782458777600